Utility of CT texture for identification of FGFR2 fusion in cholangiocarcinoma: A radiogenomic pilot study.

被引：1
|
作者：
DeLeon, Thomas
Borad, Mitesh J.
Wu, Teresa
Li, Jing
Zwart, Christine M.
Yang, George
Holeman, Scott
Silva, Alvin C.
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Mayo Clin, Scottsdale, AZ USA
[3] Mayo Clin, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15626
引用
收藏
页数：5
相关论文
共 50 条
  • [41] FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
    Patel, Timil H.
    Marcus, Leigh
    Horiba, M. Naomi
    Donoghue, Martha
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Schuck, Robert N.
    Li, Yangbing
    Zhang, Xinyuan
    Zirkelbach, Jeanne Fourie
    Charlab, Rosane
    Liu, Jiang
    Yang, Yuching
    Lemery, Steven J.
    Pazdur, Richard
    Theoret, Marc R.
    Fashoyin-Aje, Lola A.
    CLINICAL CANCER RESEARCH, 2023, 29 (05) : 838 - 842
  • [42] NTAS120, a covalently-binding FGFR inhibitor (FGFRi), overcomes resistance to BGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma
    Goyal, Lipika
    Liu, Leah Y.
    Lennerz, Jochen K.
    Harding, James J.
    Huang, Jerry
    Winkler, Robert
    Hiroshi, Hirai
    Ting, David T.
    Juric, Dejan
    Corcoran, Ryan B.
    El-Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Clinicopathological nomogram for predicting fibroblast growth factor receptor 2 (FGFR2) gene fusion/rearrangement (F/R) in intrahepatic cholangiocarcinoma (iCCA)
    Bensi, M.
    Giannarelli, D.
    Bagala, C.
    Niger, M.
    Bergamo, F.
    Barone, D.
    Rizzato, M. D.
    Nichetti, F.
    Spring, A.
    De Rosa, A.
    Beccia, V.
    Ricagno, G.
    Pircher, C. C.
    Ardito, F.
    Barbaro, B.
    Giuliante, F.
    Martinelli, E.
    De Braud, F. G. M.
    Lonardi, S.
    Tortora, G.
    Salvatore, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S229 - S229
  • [44] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Park, J. O.
    Meng, D. T. Wai
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Cassier, P.
    Kamath, S. D.
    Dotan, E.
    Kim, R.
    Sahai, V.
    Liao, C-Y.
    Millward, M.
    Roda Perez, D.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1461 - S1462
  • [45] Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
    Hollebecque, A.
    Borad, M.
    Goyal, L.
    Schram, A.
    Park, J. O.
    Cassier, P. A.
    Kamath, S. D.
    Meng, D. T. Wai
    Dotan, E.
    Kim, R.
    Sahai, V.
    Oh, D-Y.
    Liao, C-Y.
    Millward, M.
    Perez, D. Roda
    Ferte, C.
    Blakesley, R.
    Wolf, B.
    Subbiah, V.
    Kelley, R. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1381 - S1381
  • [46] Pemazyre® (Pemigatinib) is available in Germany for the Treatment of Adults with locally advanced or metastatic Cholangiocarcinoma with Fusion or Rearrangement of the Fibroblast Growth Factor Receptor 2 (FGFR2)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 367 - 367
  • [47] A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Xu, Jianming
    Xiong, Jianping
    Gu, Shanzhi
    Niu, Zuoxing
    Yin, Fei
    Sun, Beicheng
    Zhang, Lan
    Zhou, Fuxiang
    Hao, Chunyi
    Pan, Yueyin
    Qiu, Wensheng
    Gao, Yi
    Ren, Yongxin
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma (vol 69, pg 131, 2019)
    Lamberti, Dante
    Cristinziano, Giulia
    Porru, Manuela
    Leonetti, Carlo
    Egan, Jan B.
    Shi, Chang-Xin
    Buglioni, Simonetta
    Amoreo, Carla A.
    Castellani, Loriana
    Borad, Mitesh J.
    Alema, Stefano
    Anastasi, Sergio
    Segatto, Oreste
    HEPATOLOGY, 2019, 69 (02) : 925 - 925
  • [49] Identification of FGFR2/3 fusions from clinical cfDNA NGS using a de novo fusion caller.
    Yablonovitch, Arielle
    Gnerre, Sante
    Kiedrowski, Lesli Ann
    Yen, Jennifer
    Liu, Leo
    Helman, Elena
    Fairclough, Stephen R.
    Nagy, Rebecca
    Chudova, Darya
    Talasaz, AmirAli
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Agreement between FGFR2 immunohistochemistry assays and fluorescence in situ hybridization (FISH) in metastatic gastric cancer: A comparison study.
    Raskin, Grigory A.
    Mukhina, Marina S.
    Kravtsova, Elena D.
    Tjulandin, Sergei
    Tsimafeyeu, Ilya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 301 - 301
12345